The Feasibility of Inpatient Geriatric Assessment for Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia

被引:104
|
作者
Klepin, Heidi D. [1 ]
Geiger, Ann M. [2 ]
Tooze, Janet A. [2 ]
Kritchevsky, Stephen B. [3 ]
Williamson, Jeff D. [3 ]
Ellis, Leslie R. [1 ]
Levitan, Denise [1 ]
Pardee, Timothy S. [1 ]
Isom, Scott [2 ]
Powell, Bayard L. [1 ]
机构
[1] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Div Publ Hlth Sci, Winston Salem, NC 27157 USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Sect Geriatr & Gerontol, Winston Salem, NC 27157 USA
关键词
geriatric assessment; acute myelogenous leukemia; cancer; functional status; elderly; ACUTE MYELOID-LEUKEMIA; ELDERLY CANCER-PATIENTS; INTENSIVE CHEMOTHERAPY; PHYSICAL PERFORMANCE; KNEE OSTEOARTHRITIS; COMPLETE REMISSION; COMORBIDITY INDEX; GROUP-B; TRIAL; AGE;
D O I
10.1111/j.1532-5415.2011.03614.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To test the feasibility and utility of a bed-side geriatric assessment (GA) to detect impairment in multiple geriatric domains in older adults initiating chemotherapy for acute myelogenous leukemia (AML). DESIGN: Prospective observational cohort study. SETTING: Single academic institution. PARTICIPANTS: Individuals aged 60 and older with newly diagnosed AML and planned chemotherapy. MEASUREMENTS: Bedside GA was performed during inpatient exmination for AML. GA measures included the modified Mini-Mental State Examination; Center for Epidemiologic Studies Depression Scale; Distress Thermometer, Pepper Assessment Tool for Disability (includes self-reported activities of daily living (ADLs), instrumental ADLs, and mobility questions); Short Physical Performance Battery (includes timed 4-m walk, chair stands, standing balance); grip strength, and Hematopoietic Cell Transplantation Comorbidity Index. RESULTS: Of 54 participants (mean age 70.8 +/- 6.4) eligible for this analysis, 92.6% completed the entire GA battery (mean time 44.0 +/- 14 minutes). The following impairments were detected: cognitive impairment, 31.5%; depression, 38.9%; distress, 53.7%; impairment in ADLs, 48.2%; impaired physical performance, 53.7%; and comorbidity, 46.3%. Most were impaired in one (92.6%) or more (63%) functional domains. For the 38 participants rated as having good performance status according to standard oncologic assessment (Eastern Cooperative Oncology Performance Scale score <= 1), impairments in individual GA measures ranged from 23.7% to 50%. Significant variability in cognitive, emotional, and physical status was detected even after stratification according to tumor biology (cytogenetic risk group classification). CONCLUSION: Inpatient GA was feasible and added new information to standard oncology assessment, which may be important for stratifying therapeutic risk in older adults with AML. J Am Geriatr Soc 59:1837-1846, 2011.
引用
收藏
页码:1837 / 1846
页数:10
相关论文
共 50 条
  • [21] CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA IN CHILDREN AND ADULTS - VAPA UPDATE
    WEINSTEIN, HJ
    MAYER, RJ
    ROSENTHAL, DS
    CORAL, FS
    CAMITTA, BM
    GELBER, RD
    BLOOD, 1983, 62 (02) : 315 - 319
  • [22] Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia
    Hui-Chi Hsu
    Jyh-Pyng Gau
    Jacqueline Ming Liu
    Wing-Keung Chau
    Chao-Hung Ho
    Advances in Therapy, 2001, 18 : 67 - 74
  • [23] Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia
    Hsu, HC
    Gau, JP
    Liu, JM
    Chau, WK
    Ho, CH
    ADVANCES IN THERAPY, 2001, 18 (02) : 67 - 74
  • [24] Can we incorporate geriatric assessment in the management of acute lymphoblastic leukemia in older adults?
    Loh, Kah Poh
    Liesveld, Jane L.
    O'Dwyer, Kristen M.
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (04) : 296 - 301
  • [25] HIGH-DOSE CYTARABINE AND DAUNORUBICIN INDUCTION AND POSTREMISSION CHEMOTHERAPY FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA IN ADULTS
    PHILLIPS, GL
    REECE, DE
    SHEPHERD, JD
    BARNETT, MJ
    BROWN, RA
    FREILAHR, DA
    KLINGEMANN, HG
    BOLWELL, BJ
    SPINELLI, JJ
    HERZIG, RH
    HERZIG, GP
    BLOOD, 1991, 77 (07) : 1429 - 1435
  • [26] Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML)
    Klepin, Heidi D.
    Tooze, Janet
    Pardee, Timothy
    Ellis, Leslie Renee
    Berenzon, Dmitriy
    Howard, Dianna
    Demark-Wahnefried, Wendy
    Mihalko, Shannon
    Rejeski, William Jack
    Powell, Bayard L.
    Kritchevsky, Stephen
    BLOOD, 2015, 126 (23)
  • [27] Geriatric Assessment in Older Patients with Acute Myeloid Leukemia
    Loh, Kah Poh
    Klepin, Heidi D.
    CANCERS, 2018, 10 (07):
  • [28] Homoharringtonine, cytarabine and cyclopbosphamide in patients with acute myelogenous leukemia for induction chemotherapy
    Qiao, ZH
    Su, LP
    Jia, HF
    Liu, GJ
    Pei, YH
    BLOOD, 2002, 100 (11) : 259B - 259B
  • [29] PHARMACOKINETICS OF AMSACRINE IN PATIENTS RECEIVING COMBINED CHEMOTHERAPY FOR TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA
    JURLINA, JL
    VARCOE, AR
    PAXTON, JW
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 14 (01) : 21 - 25
  • [30] Predicting Chemotherapy Toxicity in Older Adults and the Importance of Geriatric Assessment
    Lagro, Joep
    Studenski, Stephanie A.
    Rikkert, Marcel G. M. Olde
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) : 560 - 560